One of the factors influencing the efficacy of tumour cell vaccines is the site of immunization. We have shown previously that gene-modified vaccines delivered directly inside the spleen induced antigen cross-presentation by splenic antigen-presenting cells (not B cells). Here, we examined the interaction between splenic CD11c + cells and antigen-specific CD4 + T cells. We used tumour cells expressing ovalbumin (OVA), a situation where CD4 + T-cell help is required for the generation of a cytotoxic T lymphocyte response. Using in vivo bioluminescence imaging of luciferase-expressing EL4-OVA cells, we could demonstrate that tumour cells were located exclusively inside the spleen following intrasplenic injection. We showed that after intra- + cells can downregulate splenic specific CD4 + T-cell response thereby leading to a decrease in antitumour systemic immunity.
One of the factors influencing the efficacy of tumour cell vaccines is the site of immunization. We have shown previously that gene-modified vaccines delivered directly inside the spleen induced antigen cross-presentation by splenic antigen-presenting cells (not B cells). Here, we examined the interaction between splenic CD11c + cells and antigen-specific CD4 + T cells. We used tumour cells expressing ovalbumin (OVA), a situation where CD4 + T-cell help is required for the generation of a cytotoxic T lymphocyte response. Using in vivo bioluminescence imaging of luciferase-expressing EL4-OVA cells, we could demonstrate that tumour cells were located exclusively inside the spleen following intrasplenic injection. We showed that after intra- 
Introduction
Mouse models investigating systemic immunity against tumours after immunization with gene-modified tumour cells or dendritic cells abound. 1, 2 Our previous studies using tumour cell vaccines expressing b-galactosidase (b-gal) as surrogate antigen demonstrated that although tumour cells are potentially capable of presenting their antigens, 3, 4 they predominantly served solely as source of antigens. [5] [6] [7] The tumour-derived antigen was taken up and cross-presented by host antigen-presenting cells (APCs) 5, 6, 8, 9 even when the site of tumour cell immunization was the spleen. 7 Moreover, intrasplenic immunization 7 conferred less protection than subcutaneous immunization both in wild-type and B cell-deficient mice. 10 These findings strongly supported that it was a non-B-cell APC within the spleen that was involved in antigen cross-presentation, a notion compatible with the report that antigen presentation in the spleen is not due to B cells 11 and with the knowledge of the central role played by dendritic cells as APC. [12] [13] [14] [15] Given the continuous and rapid migration of dendritic cells (DC) from the periphery to lymphoid organs and their short life span, it is difficult to determine exactly the nature and origin of the CD11c + DC cell population found in the steady state in a lymphoid organ like the spleen. To study splenic CD11c + cells, we chose to deliver directly gene-modified ovalbumin (OVA)-expressing tumour cells to resident splenic APC using intrasplenic injection. We could demonstrate that intrasplenic immunization alone did not upregulate the CD86 low , CD40 low or classII low expression on CD11c + cells. As reported previously, 16, 17 in vivo immature CD11c + cells engulfed and processed apoptotic T/SA-OVA tumour cells and presented the class I OVA-derived peptide SIINFEKL on their cell surface.
It is controversial whether CD8 + T-cell tolerance [18] [19] [20] results from an interaction between CD8 + T cells and immature CD11c
+ cells 21 or quite the reverse, with mature CD11c + cells. 22 However, in both cases, one can assume that CD4 + T-cell tolerance ensues from an encounter with immature CD11c + cells and this may generate regulatory T cells. 23, 24 Suppressive functions have been ascribed to both CD25 + and CD25 À CD4 + T cells [25] [26] [27] and to the expression of CTLA-4. 27, 28 Moreover, there are reports on the secretion of IL-10 or TGF-b by suppressive T-cell subsets. 24, 29 Here, we confirm using in vivo bioluminescence imaging 30 
Results
In vivo bioluminescence imaging confirmed splenic localization of luciferase-expressing tumour cells
Live luciferase-expressing EL4-OVA (EG7) tumour cells were injected intrasplenically into C57BL/6 mice. Using a Hamamatsu 1394 Aequaria Imager in vivo bioluminescence imaging confirmed the presence of tumour cells locally inside the spleen. The tumour cells were still visible locally 6 days after injection. Although tumour cell diffusion to the liver lobes cannot be formally excluded, abdominal views did not reveal any bioluminescence over the liver lobes at any time point. Three time points, 2 h, on day 2 and day 6 following splenic injection are displayed in Figure 1 .
In vivo splenic CD11c
+ cells can engulf, process and present the gene-modified tumour cell-derived antigen OVA
To demonstrate cross-presentation, H-2 bxd mice were used since the OVA antigen is presented exclusively by class I H-2 b molecules (expressed exclusively on host APC) and not by class I H-2 d molecules (found also on T/SA-OVA tumour cells).
The monoclonal antibody (mAb) 25-D1 specifically detects the class I K b -OVA-derived peptide SIINFEKL complex on the surface of APCs. This antibody is used for determining the number of peptide-class I complexes on APCs as well as identifying APC in cell mixtures and phenotyping them.
Naive H-2 bxd mice were immunized intrasplenically with tumour cells and from day 1 to 6, spleens were removed and immediately double stained with CD11c and 25-D1 antibodies. The presence of the K b -SIINFEKL complex on CD11c + cells was the strongest on day 2 following immunization and is shown in Figure 2 .
The gated population of K 16, 17 Following intrasplenic immunization, there was no in vivo upregulation of CD86, CD40 or class II expression on splenic CD11c + cells
As described above, spleens were removed 2 days after intrasplenic immunization and stained directly for in vivo control Hrs+2 Day+2 Day+6 Figure 1 Bioluminescence imaging of luciferase-expressing EG7 tumour cell line following intrasplenic injection. Mice were operated and 4 Â 10 7 live EG7-luciferase + tumour cells were injected directly into the spleen. Bioluminescence imaging of the mice was performed 2 h, on days 2 and 6 after injection. The control mouse was injected with PBS. PBS, phosphate-buffered saline. 
Counts
Cell number + splenic cells is shown by black curves. In vitro expression after 1 day of in vitro culture is shown by the grey shaded curves. Staining with isotype control mAb is displayed by broken lines. This is one representative experiment of three experiments. FITC, fluorescein; OVA, ovalbumin; PE, phycoerythrin.
Splenic CD11c and CD4 T-cell interaction and tumour cell vaccine S Cayeux et al
It has been reported previously that in vitro manipulation of dendritic cells induced an upregulation of surface molecules. 33 Here, we demonstrate that the in vivo surgical manipulation of the spleen and intrasplenic injection of tumour cells did not induce an upregulation of CD86 and CD40, molecules that are used as markers of DC maturation and activation and whose expression influences the outcome of interactions between DC and T cells. 21, 22 In an in vitro proliferation assay, MACS-sorted splenic -FITC cells were gated and the expression of the above molecules is displayed (grey shaded curves) together with the staining with isotype control mAb (black curves). This is one experiment of four separate ones. FITC, fluorescein; OVA, ovalbumin; PBS, phosphate-buffered saline; PE, phycoerythrin.
Some proliferation of CD4 + KJ1-26 + cells (85.8713.2%) was observed when T/SA-mock tumour cells (c) were injected intrasplenically. However, no proliferation was observed after subcutaneous immunization with T/SAmock (98.574.8%) (e) or T/SA-OVA (99.875.6%) (f) despite the proliferation seen in lymph nodes (not shown).
Of interest is this initial and subsequently aborted in vivo proliferation that was observed after intrasplenic immunization with T/SA-OVA (d). At later time points (days 3-6) following immunization, no further proliferation could be observed (data not shown). From the above experiments, it becomes clear that splenic CD11c + cells from mice immunized intrasplenically with T/SA-OVA were able to induce potentially CD4 + KJ1-26 + cell proliferation in vivo. However, the in vivo proliferation of CD4 + KJ1-26 + cells was aborted. This limited and arrested in vivo proliferation followed by T-cell deletion has been associated with induction of tolerance. [18] [19] [20] Activated splenic CD4 + KJ1-26 + cells after intrasplenic immunization with T/SA-OVA secrete IL-10 and IL-4 and not IFN-g
As illustrated by one representative experiment in Figure  7 , in H-2 bxd DO11.10 mice immunized intrasplenically with OVA and LPS (Figures 7Dd, h, (Figures 7Cg, k) .
Clearly, presentation of OVA to CD4 + KJ1-26 + cells by splenic CD11c
+ cells induced the activation (upregulation of CD69 and CD44 and downregulation of CD62L) of splenic CD4 + KJ1-26 + cells leading to a short and abortive proliferation burst (see Figure 6 ). These splenic CD4 
Discussion
There is every reason to believe that, if available at high enough levels, all antigens can be cross-presented by host APCs. 14 Cross-presenting APCs among the CD11c + cell population within tumours 8, 34 or peripheral organs 35 have been documented. Both following subcutaneous immunization with antigen-expressing tumour cells [36] [37] [38] and when an antigen was expressed on a peripheral organ, 39 T-cell priming was shown to take place in draining lymph nodes [36] [37] [38] [39] while no T-cell priming was seen in the spleen. 39 Similarly, we found that Splenic CD11c and CD4 T-cell interaction and tumour cell vaccine S Cayeux et al b-gal-specific CTL were found in the draining lymph nodes after subcutaneous but not intrasplenic injection of gene-modified b-gal-expressing tumour cells. 7 Intrasplenic injection resulted in cross-presentation by host non-Bcell splenic APC and did not lead to systemic immunity. 7 In the present paper, we used the H- The resting splenic CD11c + cell population expressed class I and II molecules but displayed low surface expression of the costimulatory molecules CD86 and CD40. Surgical manipulation, intrasplenic injection or uptake of apoptotic cells 19 did not induce upregulation of CD86 and CD40 and CD11c + cell maturation (Figure 3 ). After in vitro transfer, CD86 and CD40 were upregulated and induced sustained proliferation of clonotype-specific CD4 + KJ1-26 + cells (Figure 4 ). 16 Although immature DC have been reported to process inadequately endocytosed antigens to form MHC class II peptide complexes for presentation to CD4 + cells, 39 in our study, the splenic CD11c + cells were able to present sufficient class II OVA peptide to activate CD4 + KJ1-26 + cells and induce transient upregulation of CD69 and CD62L downregulation ( Figure 5 ). However, this transient T-cell activation was inadequate to trigger the sustained proliferation of splenic CSFElabelled CD4 + KJ1-26 + cells in vivo ( Figure 6 ). This abortive in vivo proliferation was followed by the disappearance of CD4 + KJ1-26 + cells from the spleen, either by deletion or redistribution in other body locations. 17, 18 Most importantly, a skewing of this CD4 + KJ1-26 + response towards IL-4 and IL-10 production was observed (Figure 7) .
Both the presence of CD4 + T-cell help and mature DC are required for CTL development after cross-presentation of OVA. 40, 41 In the absence of CD4 + T cells, CD8 + cells divided and were deleted. CD4 + cells appear to modify the APC, using its CD40-ligand to signal to a CD40-expressing APC which in return cross-primes CD8 + cells. 14, 15, 21 The provision of both a signal derived from the MHC-peptide complex (signal 1) and another from costimulatory signals such as CD86 on the APC (signal 2) ensured efficient CD8 + T-cell activation. This scheme of events has been challenged by Albert et al. Of great interest would be further analysis of the above findings in a transgenic mouse model with a selfantigen. Using the present syngeneic mouse model and transplantable mouse tumour cells, it was possible to exploit the advantages offered by a well-established and characterized system and to obtain reproducible results. However, similar studies in a transgenic mouse model in which normal cells go through the stepwise process of tissue transformation, malignant progression and tumour development without external manipulation and within their original microenvironment would clearly enable a better analysis of induction of cross-tolerance. 
Materials and methods

Immunization of mice
Intrasplenic immunization was performed as described previously. 7 Shortly, tumour cells were washed in Dulbecco's PBS (D-PBS), used live or irradiated with 100 Gy and injected in a volume of 50 ml D-PBS. An OVA protein solution (4 mg/ml) was prepared in D-PBS and 200 mg OVA used for immunization combined with 50 mg LPS.
Mice were anaesthesized using ketamine and xylazin and a small incision in the skin on the left flank of the mice was performed. The peritoneal membrane was freed and through a 0.2 cm incision, by means of forceps, the spleen was pulled out gently of the peritoneal cavity and onto the peritoneal membrane. While the spleen was held by forceps, 50 ml of cell suspension was injected through the capsule inside the spleen. As the spleen swelled, the suspension was seen to diffuse both under the capsule and deeper. The surface of the capsule was wiped dry to ensure that no cell suspension leaked out. The spleen was gently slipped back inside the peritoneal cavity, the peritoneal membrane sealed (Histoacryl, Braun, Meschungen, Germany) and the skin closed with metal clips. The wound was healed within 48 h.
Flow cytometry analysis
One-, two-or three-color immunofluorescence studies were performed. Directly coupled fluorescein (FITC)-, phycoerythrin (PE)-and cytochrome (Cy)-labelled mAbs: KJI-26 (Caltag, Hamburg, Germany) K d , K b , CD69, CD25, CTLA-4, CD62L, CD44, CD11c+, CD4 (Pharmingen, Hamburg, Germany), MHC class II IA/IE (Boehringer Mannheim, Mannheim, Germany) and isotype-matched control mAbs and 25-D1 (a gift from R Germain) followed by a direct labelled second antibody. Cells were taken, washed with PBS, incubated first with Fc-blocking reagent (0.5 mg/100 ml) (CD32/16 Dianova, Hamburg, Germany) to prevent unspecific Fc binding for 3 min, then with FITC-, PE-or APC-Cy-conjugated mAbs for 30 min at 41C and washed three times for direct staining. Indirect staining with first mAb 25-D1 was followed by incubation with FITC-labelled rabbit anti-rat second antibody. Samples were analysed in the presence of propidium iodide (1 mg/ml) to exclude dead cells.
Cell isolation by MACS
Splenocytes from DO11.10 H-2 bxd mice were depleted of erythrocytes by ammonium chloride treatment. Using a CD4 + T-cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), the CD4 + were negatively selected by incubation with magnetic microbeads labelled with mAbs for the removal of macrophages (CD11b), NK cells (DX5), APCs (MHC class II) and CD8 T cells. Labelled cells were depleted using an automated separator (autoMACS, Miltenyi Biotec). For in vivo adoptive cell transfer, the purity of the preparation as determined by flow cytometry analysis (Becton Dickinson, Heidelberg, Germany) using FITC-labelled KJI-26 mAb was around 75%. For the in vitro experiments, a second round of negative selection was performed and the purity was raised to 90% or above. These freshly isolated T cells were CD69-negative and had low levels of CD44 and high levels of CD62L as determined by double staining of the FITC-labelled KJI-26 cells and were thus considered as naive (data not shown).
For the isolation of splenic CD11c + cells from immunized mice for in vitro proliferation assays, a CD11c + cell isolation kit (Miltenyi Biotec) was used. In this case, positive selection of CD11c + cells using microbeads coated with the N418 antibody was used.
Labelling of T cells with CSFE
For the preparation of CSFE-labelled CD4 + cells from H-2 bxd DO11.10 mice after positive selection using a MACS column, the cells were resuspended in PBS containing 1% bovine serum albumin (Sigma-Aldrich Chemie GmbH, Munich, Germany) at a concentration of 1 Â 10 7 cells/ml with 2 ml of a CSFE (Molecular Probes, Eugene, OR, USA) stock solution (5 mM in dimethylsulphoxide) and incubated for 10 min at 371C. The cells were washed twice with ice-cold PBS and resuspended in PBS for i.v. infusion for in vivo adoptive CD4 + T cells transfer or in complete RPMI for in vitro proliferation assays.
Staining for intracellular cytokine production
Two days following immunization, CD4 + cells were isolated using negative selection by MACS sorter. The cells were re-stimulated in vitro with the OVA 323-339 peptide for 6 h and then washed. Using the Pharmingen kit, intracellular staining with PE-labelled IL-4, IL-10 and IFN-g was performed. Golgi-Stop was added to arrest intracellular protein breakdown (4 ml for 10 6 cells) and the cells left for 12 h at 371C and afterwards stained for surface expression of KJ1-26 (using APC-Cy-labelled mAb). After permeabilizing the cell membranes (PermWash), intracellular staining for cytokine production proceeded as described above.
Bioluminescence imaging of luciferase-positive tumour cells injected into the spleen of mice A total of 1 Â 10 7 live luciferase-expressing EL4-OVA (EG7) tumour cells in 75 ml were injected directly into the spleen as described above. Two hours, 2 and 6 days following intrasplenic injection, mice were injected intraperitoneally with luciferin (150 mg/kg, Biosynth AG, Staad, Switzerland), then anaesthesized using ketamin and xylazin (100, 10 mg/kg). The bioluminescent signal emitted from the tumour cells in vivo was measured after 2 h and on days 2 and 6 following intrasplenic injection using a Hamamatsu 1394 Aequoria Imager.
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